At Sygnature Discovery, we create exceptional scientific outcomes. For our customers, who bring life-changing medicines to patients; and for our people, who help make this possible. We’re 700+ scientists from over 50 countries, working as one across Europe and North America. With no competing internal programs, we offer total confidentiality and commitment. Over the past 20 years, we’ve earned a track record of real impact: 60+ advanced candidates, 200+ patents filed, 200+ active projects. Over 90% of our customers choose to stay with us – from biotechs racing to clinic to pharma companies that need specialised expertise for targeted challenges.
Sussex Research Laboratories Inc.
Sussex Research Laboratories Inc. (Ottawa, Canada) is a globally recognized specialist in empowering therapeutic innovation through glycoscience. The company applies its expertise in glycodesign, glycan and glycoconjugate synthesis, and linker chemistries across a wide range of therapeutic areas, including vaccine development, protein and antibody engineering, and targeted drug delivery. With 30 years of experience as a Contract Research & Development (CRO) service provider, Sussex Research supports pharmaceutical and biopharmaceutical partners in applying glycotechnology to next-generation therapeutics, including oligonucleotide, peptide, protein, lipid, and small-molecule modalities, as well as lipid nanoparticle (LNP) technologies for modern drug design and delivery. The company is also widely recognized for its enabling product portfolio of advanced glycans, glycopeptides, glycoconjugates, and targeting ligand/linker systems.
SpeciLife Inc
SpeciLife is a biospecimen sourcing hub supporting pharma and biotech teams in translational and preclinical research. We provide access to high-quality, well-annotated human samples (FFPE, fresh and frozen tissues, biofluids, and cells) through established partnerships with a global network of hospitals, clinical centers, and biobanks. Our approach is collaborative and science-driven, with our internal scientific team closely involved in feasibility assessment, quality oversight, and study alignment. We support projects across key therapeutic areas including oncology, autoimmune, infectious, and neurodegenerative diseases.
Space Peptides
Headquartered in Switzerland with global operations, Space Peptides provides End-to-End pharmaceutical Peptide CRDMO services at Premium Speed & Quality – covering discovery, process development, and GMP manufacturing. In addition, our portfolio comprises a broad range of generic Peptide APIs.
Sikich
Sikich LLP is a business and technology consultancy who’s close to 1,500 team members provide advisory, consulting, and technology services to clients in life sciences, manufacturing, professional services, and other industries. The company’s life sciences practice spans the industry and supports more than 200 life sciences clients, including biotechnology and biopharmaceutical companies, CROs, and lab diagnostic companies. As a leading life science technology consultant, we can help you streamline operations and ensure compliance, allowing stakeholders to do what they do best: develop new medicines for patients who need them. | At Sikich, we empower life sciences organizations through strategic planning, regulatory expertise, and digital modernization. From inception to commercialization, we specialize in planning, regulatory, quality, and compliance, leveraging cutting-edge technologies like Oracle NetSuite, Honeywell’s TrackWise Digital, and Kneat’s solutions to streamline operations and accelerate innovation. Our tailored approach combines deep industry knowledge with advanced digital tools, ensuring compliance, enhancing efficiency, and reducing time-to-market for life-changing therapies. A focus on built in audit trails, roles-based control and automated reporting ensure compliance with FDA 21 CFR Part 11, SOX and EU Annex 11. With a commitment to precision, integrity, and transformation, we help companies navigate complex regulatory landscapes and embrace the future of life sciences with confidence. Plan smarter. Modernize faster. Innovate with impact.
SigutLabs s.r.o.
SigutLabs, a contract research organization (CRO) located in Prague, Czech Republic, helps businesses from small start-ups to pharmaceutical giants overcome their chemistry challenges. Our agile PhD chemists specialize in custom synthesis, scale-up, and contract research across organic, bioorganic, and medicinal chemistry, with a focus on nucleotide and nucleoside chemistry, ADC linkers, and advanced applications. We excel at developing novel synthetic routes for undescribed compounds and custom synthesis of known molecules, also offering dedicated FTE chemists. We have a lean team of up to 10 employees with every chemist holding a PhD degree, which is an industry-leading scientific staff ratio. All our experts studied at prestigious universities and have extensive experience in organic and medicinal chemistry from top international institutions. Our cutting-edge labs prioritize a sustainable future with eco-friendly practices and invest in top-tier equipment to handle your most complex projects. Products from our inventory are available for purchase through our e-shop, ensuring super-fast and secure delivery worldwide. Founded in 2011, SigutLabs has grown from a small lab to a partner of choice for leading pharmaceutical and Silicon Valley companies. We played a major role in the fight against COVID-19 by developing a new synthetic pathway of remdesivir for research in just four months, and were recognized for our achievements with the 2023 Company of the Year award (Central Bohemia region). Fueled by a vision to build on the legacy of Czech chemistry, exemplified by Prof. Antonín Holý and his groundbreaking molecule tenofovir, we aim to re-establish the Czech Republic’s position on the global chemistry map. We can tackle your toughest challenges with our team’s diverse chemistry experience, including: ADC linkers Heterocyclic chemistry Palladium-catalyzed reactions Organometallic chemistry Nucleoside/nucleotide chemistry Fluorine chemistry Photochemistry Supramolecular chemistry Total synthesis of natural products Modification of enzyme substrates/inhibitors Visit our website at www.sigutlabs.com to see how SigutLabs frees hands, saves costs, and accelerates your projects with our outsourced chemistry expertise. Follow us on LinkedIn to see the latest news. | x
Shanghai Taichu Biotechnology Co., Ltd.
Taichu group was founded in 2020, providing contract research, development and manufacturing services to pharmaceutical and biotech companies. Our service platforms include early discovery and design of complex antibodies such as multispecific antibodies, nanobodies, fusion proteins etc. Our GLP- and AAALAC- certified animal facility provides preclinical studies (PK/PD), safety evaluation (Toxicology) for a various modality of drug candidates, such as small molecules, biologics, ADC, CGT products, and RNAi, ASO, mRNA molecules. For development and manufacturing of complex antibodies, our CDMO (Tarlead) has experienced teams, well-established laboratories and facility for process development, drug substance production and drug product manufacturing, ready to meet your needs and timelines. | Taichu Group is a biotechology enterprise with a core advantage in “CRO+CDMO integrated services”, providing end-to-end solutions for global innovative drug development from early discovery through preclinical research. Headquartered in Shanghai’s Lingang Special Area, the Group operates through its subsidiaries: Taichu Bio (Pre-Clinical Research), AceMab Ltd (Antibody Discovery & Design), Tarlead Biologics (Biologics Development & Manufacturing), TJR Bio (Nucleic Acid Drug Process & Manufacturing), and Taichu (Shenzhen) (Innovative Therapeutic Development Advisory). Guided by the philosophy “Advocate of Ethics and Integrity, Quest for Verity”, we streamline R&D workflows and accelerate therapeutic advancement for global partners. Our synergistic service model bridges key gaps between discovery and commercialization, reinforcing our role as a strategic enabler in the biopharmaceutical innovation value chain.
Shanghai OPM Biosciences Co., Ltd
OPM Biosciences (Stock Code: 688293) is a leading provider of Cell Culture Media (CCM) and CDMO (Contract Development and Manufacturing Organization) services. We offer an integrated solution to meet the needs of biopharmaceutical companies worldwide. OPM was established in 2013 dedicated to total cell culture solution development, which has resulted in our fast growth. We are proud to be the first listed CCM company in China and committed to being a total solution provider in biologics development. Our management system is certified to ISO9001:2015 by TÜV NORD. We have four fully cGMP-compliant plants, covering an overall area of 18,000m². Currently, we are constructing a new 30,000m² headquarters to meet the growing demand for our products and services. OPM is becoming a strategic partner of biopharmaceutical companies worldwide, and our dedication to quality and innovation ensures that we continue to be a trusted partner in the industry. Our CCM solutions are renowned for their innovative chemically-defined/serum-free media design and manufacturing. We offer a range of products and services, including proprietary commercial media, customized formulations, and OEM solutions for our clients’ unique cell lines. Our exceptional performance has established us as the preferred supplier for over 230 biologics (IND or BLA) worldwide. In addition, OPM’s CDMO services provide efficient End-to-End solutions for biotherapeutic protein development and manufacturing. Our cGMP-compliant facilities support all stages of biologics development, from antibody discovery to IND and BLA manufacturing up to 2000L. Our dedicated team of experienced scientists is committed to excellence and has contributed to the development of over 200 biologics, supporting global clients in achieving successful IND applications with the FDA and NMPA.